ユーロジェン・ファーマのニュース一覧

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)

Yahoo Finance2024/12/31 20:06

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Benzinga2024/12/06 20:16

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma2024/12/06 13:00

UroGen Pharma Announces UGN-102 Long-Term Results In The Phase 3 ENVISION Trial, Potentially Paving The Way For First FDA-Approved Treatment For LG-IR-NMIBC; UGN-102 Demonstrated 82.3% Duration Of Response At 12 Months In Patients Who Achieved...

Benzinga2024/12/06 04:18

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UroGen Pharma2024/12/05 13:00

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen Pharma2024/12/02 13:00

UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO

Benzinga2024/11/26 21:09

New Data From a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response With JELMYTO

UroGen Pharma2024/11/26 13:00

Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%

Simply Wall St2024/11/18 19:14

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary

Futuニュース2024/11/07 06:21

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

Earnings Call Transcripts2024/11/07 06:12

TD Cowenはユーロジェン・ファーマ(URGN.US)のレーティングを強気に据え置き、目標株価を35ドルにした

TD CowenのアナリストTara Bancroftは$UroGen Pharma Ltd(URGN.US)$のレーティングを強気に据え置き、目標株価を35ドルにした。TipRanksのデータによると、このアナリストの最近1年間の的中率は47.8%、平均リターンは16.2%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している

Futuニュース2024/11/07 04:31

EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Analyst Upgrades2024/11/07 00:19

UroGen Pharma Analyst Ratings

Benzinga2024/11/07 00:19

ユーロジェン・ファーマ | 10-Q：Q3 2024 四半期報告書

SEC2024/11/06 21:07

ユーロジェン・ファーマ | 8-K：UroGenファーマは、2024年第3四半期の決算と、2025年にUGN-102が発売される可能性を含むビジネスのハイライトを報告しています

SEC2024/11/06 21:07

UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range

Benzinga2024/11/06 21:05

UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate

Benzinga2024/11/06 21:01

Press Release: UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Dow Jones2024/11/06 21:00

UroGen Pharma 3Q Loss $23.7M >URGN

Dow Jones2024/11/06 21:00